Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Dec 21, 2020; 26(47): 7538-7549
Published online Dec 21, 2020. doi: 10.3748/wjg.v26.i47.7538
Table 1 Clinical characteristics of study participants
ParameterALC (n = 142)
NAFLD (n = 92)
Controls (n = 68)
Together (n = 302)
Sex (F/M)36/10633/5936/32105/197
Age (yr), (mean ± SD; median; min-max)54 ± 12; 55; 31-8460 ± 15; 61; 22-9046 ± 16; 45; 20-8554 ± 15; 55; 20-90
BMI (kg/m2) (mean ± SD; median; min-max)25.89 ± 9.31; 25.91; 16.7-36.7129.49 ± 4.9; 28.7; 16.26-43.0121.95 ± 2.62; 22.45; 16.18-24.86-
DM type 20/14222/92--
AH32/14246/92--
Table 2 Results of used scores in research group
Score
ALC
NAFLD
Mean
SD
Median
Min
Max
Mean
SD
Median
Min
Max
MELD17816645-----
BARD-----21204
NAFLD fibrosis score------1.361.5-1.16-5.831.74
Table 3 Results of hematological indices and serological (indirect and indirect) markers of liver fibrosis in examined patients
Parameter (reference range)ALC
NAFLD
Controls
MeanSDMedianMinMaxMeanSDMedianMinMaxMeanSDMedianMinMax
NLR6.36.994.09d0.5349.843.42.842.63d0.1717.331.971.091.770.816.2
PLR120.8587.1899.49d0.7435.82182.78128.93139.558.94742.86154.8864.92141.5956.9327.27
MPR0.150.290.09d0.023.280.040.020.030.010.10.030.010.030.020.06
AAR2.191.161.89d0.187.571.030.550.91a0.233.11.150.431.10.432.86
APRI4.357.022.43d0.1568.380.811.040.48d0.137.670.250.130.230.110.86
FIB-411.6725.466.34d0.69287.591.921.631.57d0.2311.580.850.540.710.283.27
GPR15.7328.546.65d0.18188.712.765.570.54d0.1335.410.250.10.240.060.63
PICP (ng/mL)63.3231.5360.536.15161.1252.1427.5646.0810.10147.2758.2637.3944.180202.89
PIIINP (ng/mL)9.284.338.4b2.4328.6511.413.9911.002.1825.3511.075.6110.254.3543.63
PDGF-AB (pg/mL)18280.478061.0617343.71c1925.6842823.8426858.687335.0926682.8310821.0249808.0723579.2810068.825623.21638.247758.7
TGF-α (pg/mL)2445.3313.77d0.872507.0917.8919.1812.09d1.39142.6328.4417.2124.591.3193.55
Laminin (ng/mL)976.34705.29832.06a101.9333301.0048230.24375.23d72.871335.92718.24386.1663.27140.881813.88
Table 4 Correlations between examined parameters in examined alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients
PairR SpearmanP value
ALC
MPR and APRI0.691c
MPR and FIB-40.776c
NLR and AAR0.173a
NLR and GPR0.183a
PLR and APRI-0.535c
PLR and FIB-4-0.557c
MPR and MELD0.343d
NLR and MELD0.379d
PLR and MELD-0.235b
NLR and PIIINP-0.183a
MPR and PDGF-AB-0.366c
PLR and PDGF-AB0.272b
NAFLD
MPR and APRI0.557d
MPR and FIB-40.603d
MPR and GPR0.303b
MPR and NFS0.587d
Table 5 Diagnostic accuracy of hematological indices in examined alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients
Parameter
ALC
NAFLD
Diagnostic accuracy
Diagnostic accuracy
AUC
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
P value
AUC
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
P value
NLR0.82178808963d0.72572717765d
PLR0.67535979642d0.52888185952-
MPR0.92985949775d0.54739787149-